IONS - Ionis to host 2024 virtual Annual Meeting of Stockholders
PR Newswire
CARLSBAD, Calif. , May 15, 2024 /PRNewswire/ -- Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced that management will conduct its 2024 virtual Annual Meeting of Stockholders followed by a general corporate update on Thursday, June 6, 2024 .
The agenda for the event is as follows:
- 5:00 p.m. – 5:15 p.m. ET ( 2:00 p.m. – 2:15 p.m. PT ) – Virtual Annual Meeting of Stockholders
- All stockholders of record at the close of business on April 8, 2024 , are invited to participate in the virtual Annual Meeting webcast, which will be broadcast live at http://www.virtualshareholdermeeting.com/IONS2024 .
- Stockholders of record will receive an official proxy card from their brokerage firm. Each proxy card contains a 16-digit control number required to log-in, vote and submit questions during the webcast.
- Ionis does not provide proxy cards or have access to proxy card information, including 16-digit control numbers. For help obtaining a proxy card or to locate their control number or for instructions to access the webcast, stockholders of record should contact their brokerage firm before Thursday, May 23 .
- A help line will be available on the registration page of the live webcast for participants requiring technical assistance in accessing or participating during the live event. There will not be a replay of this session.
- All stockholders of record at the close of business on April 8, 2024 , are invited to participate in the virtual Annual Meeting webcast, which will be broadcast live at http://www.virtualshareholdermeeting.com/IONS2024 .
- 5:30 p.m. ET ( 2:30 p.m. PT ) – Virtual corporate update
- Brett P. Monia , Ph.D., Ionis' chief executive officer, will provide a general corporate update followed by a question-and-answer session.
- All interested parties may access the webcast live at https://event.webcasts.com/starthere.jsp?ei=1659973&tp_key=9ca016319a . An archived replay of the webcast will be posted for a limited time following the meeting at that same address.
- Questions for management may be submitted in advance of the webcast and will be addressed during the question-and-answer portion of the webcast. Please submit questions via email to IonisAnnualMeeting@ionisph.com by Tuesday, June 4 . Questions not addressed during the webcast will be answered by email following the meeting.
- Brett P. Monia , Ph.D., Ionis' chief executive officer, will provide a general corporate update followed by a question-and-answer session.
About Ionis Pharmaceuticals, Inc.
For three decades, Ionis has invented medicines that bring better futures to people with serious diseases. Ionis currently has five marketed medicines and a leading pipeline in neurology, cardiology, and other areas of high patient need. As the pioneer in RNA-targeted medicines, Ionis continues to drive innovation in RNA therapies in addition to advancing new approaches in gene editing. A deep understanding of disease biology and industry-leading technology propels our work, coupled with a passion and urgency to deliver life-changing advances for patients. To learn more about Ionis, visit Ionispharma.com and follow us on X (Twitter) and LinkedIn .
Ionis Pharmaceuticals Investor Contact:
D. Wade Walke , Ph.D. – info@ionisph.com – 760-603-2331
Ionis Pharmaceuticals Media Contact:
Hayley Soffer – CorporateCommunications@ionisph.com – 760-603-4679
SOURCE Ionis Pharmaceuticals, Inc.
News, Short Squeeze, Breakout and More Instantly...
Market Wire News is a media platform, the information on this page was provided by PR Newswire via Quote Media. Read our full disclaimer.